Polycystic Ovarian Syndrome Treatment Market Size, Share & Trends Report By Drugs (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants, Anti-obesity), By Surgery, And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Research Methodology
                 1.1 Information procurement
                 1.2 Data Analysis
                 1.3 Approaches for market estimation
                     1.3.1 Approach 1: Demand Analysis & Bottom up Approach
                     1.3.2 Approach 2: Top down market estimation
                     1.3.3 Approach 3: Commodity flow and bottom up market estimation
                     1.3.4 Approach 4: KoL perspective based market sizing
Chapter 2 Executive Summary
                 2.1 Market Snapshot
Chapter 3 Industry Outlook
                 3.1 Market segmentation & scope
                 3.2 Market Driver Analysis
                     3.2.1 Rising prevalence of polycystic ovarian syndrome
                     3.2.2 Genetic Defects
                     3.2.3 Rising awareness among patients
                 3.3 Market Restraint Analysis
                     3.3.1 Adverse effects associated with treatment
                 3.4 Penetration & growth prospect mapping
                 3.5 Cancer Diagnostics - SWOT Analysis, By Factor (political & legal, economic and technological)
                 3.6 Industry Analysis - Porter’s
                 3.7 Pipelines Analysis, Phase III: PCOS Treatment Molecules
Chapter 4 Polycystic Ovarian Syndrome Market: Drug Estimates & Trend Analysis
                 4.1 Polycystic Ovarian Syndrome (PCOS) Treatment Market Drug Class Outlook Key Takeaways
                 4.2 Polycystic Ovarian Syndrome Market: Drug Type Movement Analysis
                 4.3 Contraceptives & Antiandrogens
                     4.3.1 Contraceptives & anti-androgens market, 2014 - 2025 (USD Million)
                     4.3.2 Provera
                         4.3.2.1 Provera market, 2014 - 2025 (USD Million)
                     4.3.3 Yasminell
                         4.3.3.1 Yasminell market, 2014 - 2025 (USD Million)
                     4.3.4 Clomid
                         4.3.4.1 Clomid market, 2014 - 2025 (USD Million)
                     4.3.5 Aldactone
                         4.3.5.1 Aldactone market, 2014 - 2025 (USD Million)
                     4.3.6 Diane 35
                         4.3.6.1 Diane 35 market, 2014 - 2025 (USD Million)
                     4.3.7 Others
                         4.3.7.1 Others market, 2014 - 2025 (USD Million)
                 4.4 Insulin Sensitizing Agents
                     4.4.1 Insulin sensitizing agents market, 2014 - 2025 (USD Million)
                     4.4.2 Glucophase XR
                         4.4.2.1 Glucophase XR market, 2014 - 2025 (USD Million)
                     4.4.3 Kombiglyze
                         4.4.3.1 Kombiglyze market, 2014 - 2025 (USD Million)
                     4.4.4 Others
                         4.4.4.1 Others market, 2014 - 2025 (USD Million)
                 4.5 Anti-Depressants
                     4.5.1 Anti-depressants market, 2014 - 2025 (USD Million)
                 4.6 Anti-obesity agents
                     4.6.1 Anti-obesity agents market, 2014 - 2025 (USD Million)
Chapter 5 Polycystic Ovarian Syndrome Market: Surgery Type Estimates & Trend Analysis
                 5.1 Polycystic Ovarian Syndrome (PCOS) Treatment Market Surgery Class Outlook Key Takeaways
                 5.2 Polycystic Ovarian Syndrome Market: Surgery Movement Analysis
                 5.3 Ovarian Wedge Resection
                     5.3.1 Ovarian wedge resection market, 2014 - 2025 (USD Million)
                 5.4 Laparoscopic Ovarian Drilling
                     5.4.1 Laparoscopic ovarian drilling market, 2014 - 2025 (USD Million)
Chapter 6 Polycystic Ovarian Syndrome Market: Regional Estimates & Trend Analysis, by Drug and Surgery Type
                 6.1 Polycystic Ovarian Syndrome Market: Regional Movement Analysis
                 6.2 North America
                     6.2.1 North America market, 2014 - 2025 (USD Million)
                     6.2.2 U.S.
                         6.2.2.1 U.S. market, 2014 - 2025 (USD Million)
                 6.3 Canada
                     6.3.1 Canada market, 2014 - 2025 (USD Million)
                 6.4 Europe
                     6.4.1 Europe market, 2014 - 2025 (USD Million)
                     6.4.2 U.K.
                         6.4.2.1 U.K. market, 2014 - 2025 (USD Million)
                     6.4.3 Germany
                         6.4.3.1 Germany market, 2014 - 2025 (USD Million)
                 6.5 Asia Pacific
                 6.6 Asia Pacific market, 2014 - 2025 (USD Million)
                     6.6.1 Japan
                     6.6.2 Japan market, 2014 - 2025 (USD Million)
                     6.6.3 China
                         6.6.3.1 China market, 2014 - 2025 (USD Million)
                 6.7 Latin America
                 6.8 Latin America market, 2014 - 2025 (USD Million)
                     6.8.1 Brazil
                         6.8.1.1 Brazil market, 2014 - 2025 (USD Million)
                     6.8.2 Mexico
                         6.8.2.1 Mexico market, 2014 - 2025 (USD Million)
                 6.9 Middle East and Africa (MEA)
                 6.10 MEA market, 2014 - 2025 (USD Million)
                     6.10.1 South Africa
                         6.10.1.1 South Africa market, 2014 - 2025 (USD Million)
Chapter 7 Competitive Landscape
                 7.1 Strategy framework
                 7.2 Company Profiles
                     7.2.1 AstraZeneca
                         7.2.1.1 Company Overview
                         7.2.1.2 Financial performance
                         7.2.1.3 Product Benchmarking
                         7.2.1.4 Strategic Initiatives
                     7.2.2 Bayer AG
                         7.2.2.1 Company Overview
                         7.2.2.2 Financial Performance
                         7.2.2.3 Product Benchmarking
                         7.2.2.4 Strategic Initiatives
                     7.2.3 Merck KGaA
                         7.2.3.1 Company Overview
                         7.2.3.2 Financial Performance
                         7.2.3.3 Product Benchmarking
                         7.2.3.4 Strategic Initiatives
                     7.2.4 Abbott
                         7.2.4.1 Company Overview
                         7.2.4.2 Financial performance
                         7.2.4.3 Product Benchmarking
                         7.2.4.4 Strategic Initiatives
                     7.2.5 Pfizer, Inc.
                         7.2.5.1 Company Overview
                         7.2.5.2 Financial Performance
                         7.2.5.3 Product Benchmarking
                         7.2.5.4 Strategic Initiatives
                     7.2.6 Sanofi
                         7.2.6.1 Company Overview
                         7.2.6.2 Financial Performance
                         7.2.6.3 Product Benchmarking
                         7.2.6.4 Strategic Initiatives
                     7.2.7 Bristol Myers Squibb Company
                         7.2.7.1 Company Overview
                         7.2.7.2 Financial Performance
                         7.2.7.3 Product Benchmarking
                         7.2.7.4 Strategic Initiatives
                     7.2.8 Teva Pharmaceutical Industries Ltd.
                         7.2.8.1 Company Overview
                         7.2.8.2 Financial Performance
                         7.2.8.3 Product Benchmarking
                         7.2.8.4 Strategic Initiatives
                     7.2.9 Novartis AG
                         7.2.9.1 Company Overview
                         7.2.9.2 Financial Performance
                         7.2.9.3 Product Benchmarking
                         7.2.9.4 Strategic Initiatives
                     7.2.10 Ferring B.V.
                         7.2.10.1 Company Overview
                         7.2.10.2 Financial Performance
                         7.2.10.3 Product Benchmarking
                         7.2.10.4 Strategic Initiatives

List of Tables

TABLE 1 North America polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 2 North America polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 3 North America polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 4 U.S. polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 5 U.S. polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 6 U.S. polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 7 Canada polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 8 Canada polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 9 Canada polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 10 Europe polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 11 Europe polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 12 Europe polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 13 U.K. polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 14 U.K. polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 15 U.K. polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 16 Germany polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 17 Germany polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 18 Germany polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 19 Asia Pacific polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 20 Asia Pacific polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 21 Asia Pacific polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 22 Japan polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 23 Japan polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 24 Japan polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 25 China polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 26 China polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 27 China polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 28 Latin America polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 29 Latin America polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 30 Latin America polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 31 Brazil polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 32 Brazil polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 33 Brazil polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 34 Mexico polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 35 Mexico polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 36 Mexico polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 37 MEA polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 38 MEA polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 39 MEA polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)
TABLE 40 South Africa polycystic ovarian syndrome treatment market, 2014 - 2025 (USD Billion)
TABLE 41 South Africa polycystic ovarian syndrome treatment market, by drugs 2014 - 2025 (USD Billion)
TABLE 42 South Africa polycystic ovarian syndrome treatment market, by surgery 2014 - 2025 (USD Billion)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary (USD Million)
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Polycystic Ovarian Syndrome Treatment: Drug Class Key Takeaways, USD Million
FIG. 16 Polycystic Ovarian Syndrome: Drug Movement Analysis, USD Million
FIG. 17 Contraceptives & anti-androgens market, 2014 - 2025 (USD Million)
FIG. 18 Provera market, 2014 - 2025 (USD Million)
FIG. 19 Yasminell market, 2014 - 2025 (USD Million)
FIG. 20 Clomid market, 2014 - 2025 (USD Million)
FIG. 21 Aldactone market, 2014 - 2025 (USD Million)
FIG. 22 Diane 35 market, 2014 - 2025 (USD Million)
FIG. 23 Others market, 2014 - 2025 (USD Million)
FIG. 24 Insulin sensitizing agents market, 2014 - 2025 (USD Million)
FIG. 25 Glucophase XR market, 2014 - 2025 (USD Million)
FIG. 26 Kombiglyze market, 2014 - 2025 (USD Million)
FIG. 27 Others market, 2014 - 2025 (USD Million)
FIG. 28 Anti-depressants market, 2014- 2025 (USD Million)
FIG. 29 Anti-obesity agents market, 2014 - 2025 (USD Million)
FIG. 30 Polycystic Ovarian Syndrome Treatment: Surgery Type, Key Takeaways, USD Million
FIG. 31 Polycystic Ovarian Syndrome: Surgery Movement Analysis, USD Million
FIG. 32 Ovarian wedge resection market, 2014 - 2025 (USD Million)
FIG. 33 Laparoscopic ovarian drilling market, 2014 - 2025 (USD Million)
FIG. 34 Regional market place: Key takeaways
FIG. 35 Polycystic Ovarian Syndrome Market: Regional Movement Analysis, USD Million
FIG. 36 North America market, 2014 - 2025 (USD Million)
FIG. 37 U.S. market, 2014 - 2025 (USD Million)
FIG. 38 Canada market, 2014 - 2025 (USD Million)
FIG. 39 Europe market, 2014 - 2025 (USD Million)
FIG. 40 U.K. market, 2014 - 2025 (USD Million)
FIG. 41 Germany market, 2014 - 2025 (USD Million)
FIG. 42 Asia Pacific market, 2014 - 2025 (USD Million)
FIG. 43 Japan market, 2014 - 2025 (USD Million)
FIG. 44 China market, 2014 - 2025 (USD Million)
FIG. 45 Latin America market, 2014 - 2025 (USD Million)
FIG. 46 Brazil market, 2014 - 2025 (USD Million)
FIG. 47 Mexico market, 2014 - 2025 (USD Million)
FIG. 48 MEA market, 2014 - 2025 (USD Million)
FIG. 49 South Africa market, 2014 - 2025 (USD Million)
FIG. 50 Strategy framework